

## Listing and evaluation of the results

51396: Dr. Endre Mikus  
LabMagister Training and Science Ltd.

Survey of 28 January 2022





Adviser:

Prof. Dr. med. Kai Gutensohn  
INSTAND e.V.  
Ubierstraße 20  
40223 Düsseldorf

Tel.: +49 160 1549548  
Mail: k.gutensohn@instand-ev.de

217

### Haematology 11 - Stem/Progenitor Cells (CD 34)

Analyte	Sample	Unit	Your value	Target value	TV-Type	Lower limit	Upper limit	Deviation	Z-Score	Meets criteria	
CD34+ Events	11	/µl	90.0	73.9	SV	59.1	88.7	21.8%	1,98	-	
	12		57.0	53.5	SV	42.8	64.2	6.5%	0,564	+	
Leucocytes	(1) 11	/µl	16434								Sample not evaluated
	(1) 12		12991								Sample not evaluated
CD45+ events (single platform)	(1) 11	/µl	15470								
	(1) 12		12439								
Viable CD45+ Events	(1) 11	/µl	15403								
	(1) 12		12381								
Viable CD34+ Events	11	/µl	85.0	70.1	SV	56.1	84.1	21.3%	2,02	-	
	12		54.0	50.1	SV	40.1	60.1	7.8%	0,725	+	
Viable CD34+ Events per viable CD45+ Events	(1) 11	%	0.550								
	(1) 12		0.430								

Analyte	Sample	Your unit	Stated value	Conversion factor	Method	Manufacturer	Device	Sample reception date	Sample processing date
CD34+ Events	11		90.0	1.00	222	BN	BN04		
	12		57.0	1.00					
Leucocytes	11		16434	1.00	222	BN	BN04		
	12		12991	1.00					
CD45+ events (single platform)	11		15470	1.00	222	BN	BN04		
	12		12439	1.00					
Viable CD45+ Events	11		15403	1.00	222	BN	BN04		
	12		12381	1.00					
Viable CD34+ Events	11		85.0	1.00	222	BN	BN04		
	12		54.0	1.00					
Viable CD34+ Events per viable CD45+ Events	11		0.550	1.00	222	BN	BN04		
	12		0.430	1.00					

(1) In general, no certificate is issued for this parameter in this EQA scheme.

## Individual summary of results

51396: Dr. Endre Mikus  
LabMagister Training and Science Ltd.

Survey of 28 January 2022



217

### Haematology 11 - Stem/Progenitor Cells (CD 34)

#### CD34+ Events (/μl, N = 87)

Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11	73.9	59.1 - 88.7	73.9	11.0	87	88.5	82.8
	12	53.5	42.8 - 64.2	53.5	11.6	87	88.5	

Rate of success: 82,8%



#### Leucocytes (/μl, N = 30)


Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11		Sample not evaluated			30		
	12		Sample not evaluated			30		

Graphical representation  
not useful

#### CD45+ events (single platform) (/μl, N = 81)


Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)	
				AVG	CV	Num.	Sam.	total
all methods	11			11966		81		
	12			11539		81		

Rate of success: 91,4%





Viable CD45+ Events (/μl, N = 90)									
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11			11579		90			
	12			11125		90			

Rate of success: 90%



Viable CD34+ Events (/μl, N = 90)										
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)			
				AVG	CV	Num.	Sam.	total		
all methods	11	70.1	56.1 - 84.1	70.1	10.5	90	91.1	85.6		
	12	50.1	40.1 - 60.1	50.1	10.7	90	87.8			

Rate of success: 85,6%



Viable CD34+ Events per viable CD45+ Events (% , N = 90)									
Collective	Sam- ple	Target value	Target range	Participants collective			Rate (%)		
				AVG	CV	Num.	Sam.	total	
all methods	11			0.615		90			
	12			0.459		90			

Rate of success: 85,6%

